keyword
MENU ▼
Read by QxMD icon Read
search

Vortioxetine and nausea

keyword
https://www.readbyqxmd.com/read/29923970/vortioxetine-overdose-in-a-suicidal-attempt-a-case-report
#1
Mario Gennaro Mazza, Aurora Rossetti, Eugenia Rossana Botti, Massimo Clerici
RATIONALE: Vortioxetine is a new multimodal antidepressant approved by the Food and Drug Administration for the treatment of Major Depressive Disorder and recently introduced in Europe. While antidepressant properties of vortioxetine and its tolerability have been demonstrated by preclinical and clinical studies data on the safety of vortioxetine after overdose are still lacking. PATIENT CONCERNS: A 50-year-old Caucasian man presenting a severe depressive episode that in a suicide attempt he took vortioxetine at 250 mg...
June 2018: Medicine (Baltimore)
https://www.readbyqxmd.com/read/29673132/the-effects-of-vortioxetine-on-cognitive-dysfunction-in-patients-with-inadequate-response-to-current-antidepressants-in-major-depressive-disorder-a-short-term-randomized-double-blind-exploratory-study-versus-escitalopram
#2
Eduard Vieta, Lasse B Sluth, Christina K Olsen
BACKGROUND: Major Depressive Disorder (MDD) is a heterogeneous disease characterized by emotional, physical and cognitive symptoms. This study explored the effects of vortioxetine versus escitalopram on outcomes of cognition, functioning and mood symptoms in depressed patients with inadequate response to current antidepressant treatment. METHODS: In this parallel-group, active-comparator study, adult patients (18-65 years, N = 101) with MDD, with inadequate response to current antidepressant monotherapy, were randomized 1:1 to 8 weeks' double-blind treatment with flexible doses (10-20mg/day) of either vortioxetine or escitalopram...
February 2018: Journal of Affective Disorders
https://www.readbyqxmd.com/read/29331703/the-effects-of-vortioxetine-on-cognitive-performance-in-working-patients-with-major-depressive-disorder-a-short-term-randomized-double-blind-exploratory-study
#3
Bernhard T Baune, Lasse B Sluth, Christina K Olsen
BACKGROUND: Major Depressive Disorder (MDD) is a complex disease characterized by emotional, physical and cognitive symptoms. We explored the efficacy of vortioxetine versus placebo on outcomes of cognition, functioning and mood symptoms in working patients with depression, using paroxetine as an active reference. METHODS: Gainfully employed patients (18-65 years, N = 152) with MDD were randomized 1:1:1 to 8 weeks' double-blind, parallel treatment either with vortioxetine (10mg/day) or paroxetine (20mg/day), or with placebo...
March 15, 2018: Journal of Affective Disorders
https://www.readbyqxmd.com/read/28499187/vortioxetine-a-review-of-the-pharmacology-and-clinical-profile-of-the-novel-antidepressant
#4
REVIEW
Magdalena Sowa-Kućma, Patrycja Pańczyszyn-Trzewik, Paulina Misztak, Rafał R Jaeschke, Katherine Sendek, Krzysztof Styczeń, Wojciech Datka, Magdalena Koperny
The aim of this paper was to review the up-to-date evidence base on pharmacology and clinical properties of vortioxetine. Vortioxetine is a novel antidepressant, approved by the US Food and Drug Administration (FDA) for the treatment of major depressive disorder (MDD). Because vortioxetine exhibits both an antidepressant and anxiolytic effect, it may be effective in treating both depressive and anxiety disorders, such as generalized anxiety disorder (GAD). Based on its pharmacodynamics profile and preclinical studies, it is believe that the drug's clinical action is mediated mainly by selective blockade of serotonin reuptake (by inhibiting the serotonin transporter [SERT]) and direct modulation of 5-HT receptors activity (such as 5-HT3 , 5-HT7 , 5-HT1D and 5-HT1B )...
August 2017: Pharmacological Reports: PR
https://www.readbyqxmd.com/read/27869048/efficacy-safety-and-tolerability-of-vortioxetine-for-the-treatment-of-major-depressive-disorder-in-patients-aged-55-years-or-older
#5
George G Nomikos, Dapo Tomori, Wei Zhong, John Affinito, William Palo
OBJECTIVE: These post hoc analyses evaluate the efficacy, safety, and tolerability of vortioxetine versus placebo in patients aged ≥55 years with major depressive disorder (MDD). METHODS: Study-level efficacy data from 12 short-term, fixed-dose, randomized, placebo-controlled trials of vortioxetine 5-20 mg/day were assessed using a random-effects meta-analysis. Adverse events (AEs), vital signs, ECG values, liver enzymes, and body weight were pooled from the same studies...
August 2017: CNS Spectrums
https://www.readbyqxmd.com/read/27781949/current-and-future-perspectives-on-the-major-depressive-disorder-focus-on-the-new-multimodal-antidepressant-vortioxetine
#6
REVIEW
Laura Orsolini, Carmine Tomasetti, Alessandro Valchera, Felice Iasevoli, Elisabetta Filomena Buonaguro, Michele Fornaro, Annastasia L C Fiengo, Giovanni Martinotti, Federica Vellante, Ilaria Matarazzo, Roberta Vecchiotti, Giampaolo Perna, Marco Di Nicola, Alessandro Carano, Andrea de Bartolomeis, Massimo Di Giannantonio, Domenico De Berardis
BACKGROUND: Vortioxetine (VRX) is a multimodal antidepressant that acts as serotonin (5HT) transporter inhibitor as well as 5HT3A and 5HT7 receptors antagonist, 5HT1A and 5HT1B receptors partial agonist. It was recently approved in the US and the EU for the treatment of adult patients with Major Depressive Disorder (MDD). OBJECTIVE: The present article aims at systematically reviewing findings of the published and unpublished research on the pharmacological properties, efficacy, safety and tolerability of oral VRX in the treatment of MDD...
2017: CNS & Neurological Disorders Drug Targets
https://www.readbyqxmd.com/read/27508501/the-safety-tolerability-and-risks-associated-with-the-use-of-newer-generation-antidepressant-drugs-a-critical-review-of-the-literature
#7
REVIEW
André F Carvalho, Manu S Sharma, André R Brunoni, Eduard Vieta, Giovanni A Fava
Newer generation antidepressant drugs (ADs) are widely used as the first line of treatment for major depressive disorders and are considered to be safer than tricyclic agents. In this critical review, we evaluated the literature on adverse events, tolerability and safety of selective serotonin reuptake inhibitors, serotonin noradrenaline reuptake inhibitors, bupropion, mirtazapine, trazodone, agomelatine, vilazodone, levomilnacipran and vortioxetine. Several side effects are transient and may disappear after a few weeks following treatment initiation, but potentially serious adverse events may persist or ensue later...
2016: Psychotherapy and Psychosomatics
https://www.readbyqxmd.com/read/27474960/a-meta-analysis-of-the-efficacy-of-vortioxetine-in-patients-with-major-depressive-disorder-mdd-and-high-levels-of-anxiety-symptoms
#8
David S Baldwin, Ioana Florea, Paula L Jacobsen, Wei Zhong, George G Nomikos
BACKGROUND: Coexisting anxiety is common in major depressive disorder (MDD) and more difficult to treat than depression without anxiety. This analysis assessed the efficacy, safety, and tolerability of vortioxetine in MDD patients with high levels of anxiety (baseline Hamilton Anxiety Rating Scale [HAM-A] total score ≥20). METHODS: Efficacy was assessed using an aggregated, study-level meta-analysis of 10 randomized, placebo-controlled, 6/8-week trials of vortioxetine 5-20mg/day in adults (18-75 years), with a study in elderly patients (≥65 years) analyzed separately...
December 2016: Journal of Affective Disorders
https://www.readbyqxmd.com/read/27143896/the-efficacy-and-safety-of-multiple-doses-of-vortioxetine-for-generalized-anxiety-disorder-a-meta-analysis
#9
Jie Fu, Lilei Peng, Xiaogang Li
OBJECTIVE: Vortioxetine is a novel antidepressant approved for the treatment of major depressive disorder by the US Food and Drug Administration in September 2013. This meta-analysis assessed the efficacy and safety of different doses of vortioxetine for generalized anxiety disorder of adults. METHODS: PubMed, Cochrane Library, PsycINFO, and Clinical Trials databases were searched from 2000 through 2015. The abstracts of the annual meetings of the American Psychiatric Association and previous reviews were searched to identify additional studies...
2016: Neuropsychiatric Disease and Treatment
https://www.readbyqxmd.com/read/27013879/the-efficacy-and-safety-of-10-mg-vortioxetine-in-the-treatment-of-major-depressive-disorder-a-meta-analysis-of-randomized-controlled-trials
#10
Guangjian Li, Xu Wang, Dihui Ma
BACKGROUND: Vortioxetine is an investigational multimodal antidepressant. We conducted this meta-analysis to assess the efficacy and safety of 10 mg vortioxetine in the treatment of major depressive disorder (MDD). METHODS: Randomized controlled trials (RCTs) published in PubMed, Web of Science, Embase, and ClinicalTrials.gov were systematically reviewed to assess the treatment effects and safety profiles of patients with MDD who were treated with 10 mg vortioxetine...
2016: Neuropsychiatric Disease and Treatment
https://www.readbyqxmd.com/read/26864543/the-safety-and-tolerability-of-vortioxetine-analysis-of-data-from-randomized-placebo-controlled-trials-and-open-label-extension-studies
#11
David S Baldwin, Lambros Chrones, Ioana Florea, Rebecca Nielsen, George G Nomikos, William Palo, Elin Reines
The safety and tolerability of vortioxetine in adults with major depressive disorder was assessed. Tolerability was based on the nature, incidence and severity of treatment-emergent adverse events (TEAEs) during acute (6/8) week treatment in 11 randomized, double-blind placebo-controlled short-term studies in major depressive disorder: six with an active reference. Symptoms following discontinuation were assessed through the Discontinuation-Emergent Signs and Symptoms checklist in three studies. Long-term (⩽52 weeks) tolerability was evaluated in five open-label extension studies...
March 2016: Journal of Psychopharmacology
https://www.readbyqxmd.com/read/26679430/vortioxetine-a-new-treatment-for-major-depressive-disorder
#12
REVIEW
K Ryan Connolly, Michael E Thase
INTRODUCTION: Vortioxetine is a structurally novel medication that has recently been approved for treatment of major depressive disorder (MDD). This medication is a serotonin reuptake inhibitor that also has a number of other potentially relevant effects on serotoninergic receptors, which may differentiate the drug's effects from those of current first-line antidepressants, such as selective serotonin reuptake inhibitors (SSRIs) and serotonin norepinephrine reuptake inhibitors (SNRIs)...
2016: Expert Opinion on Pharmacotherapy
https://www.readbyqxmd.com/read/26331383/effect-of-vortioxetine-vs-escitalopram-on-sexual-functioning-in-adults-with-well-treated-major-depressive-disorder-experiencing-ssri-induced-sexual-dysfunction
#13
RANDOMIZED CONTROLLED TRIAL
Paula L Jacobsen, Atul R Mahableshwarkar, Yinzhong Chen, Lambros Chrones, Anita H Clayton
INTRODUCTION: Sexual dysfunction is common with serotonergic antidepressants, including selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs), and does not resolve in most patients. Vortioxetine, an antidepressant with a multimodal mechanism of action, has shown low rates of sexual dysfunction in previous major depressive disorder (MDD) trials. AIM: This study compared the effects of vortioxetine and escitalopram on sexual functioning in adults with well-treated MDD experiencing treatment-emergent sexual dysfunction (TESD)...
October 2015: Journal of Sexual Medicine
https://www.readbyqxmd.com/read/26253622/differentiated-effects-of-the-multimodal-antidepressant-vortioxetine-on-sleep-architecture-part-1-a-pharmacokinetic-pharmacodynamic-comparison-with-paroxetine-in-healthy-men
#14
RANDOMIZED CONTROLLED TRIAL
Sue Wilson, Astrid-Maria Højer, Jeppe Buchberg, Johan Areberg, David J Nutt
We compared the effect of vortioxetine, paroxetine and placebo after three days of dosing on sleep architecture. This was a randomised, double-blind, four-way crossover, placebo-controlled, multiple-dose study in 24 healthy young men. Subjects received 20mg vortioxetine, 40 mg vortioxetine, 20mg paroxetine or placebo for three consecutive days in four different periods with at least three weeks between them. Polysomnography and blood sampling for pharmacokinetic analysis were performed on the pre-dose night and nights 1 and 3 of dosing in each period...
October 2015: Journal of Psychopharmacology
https://www.readbyqxmd.com/read/26035186/a-randomized-double-blind-placebo-controlled-study-of-the-efficacy-and-safety-of-2-doses-of-vortioxetine-in-adults-with-major-depressive-disorder
#15
RANDOMIZED CONTROLLED TRIAL
Atul R Mahableshwarkar, Paula L Jacobsen, Michael Serenko, Yinzhong Chen, Madhukar H Trivedi
BACKGROUND: This 8-week, randomized, double-blind, placebo-controlled study, conducted August 2010-May 2012 in the United States, evaluated the safety and efficacy of vortioxetine 10 mg and 15 mg in patients with major depressive disorder (MDD). The mechanism of action of vortioxetine is thought to be related to direct modulation of serotonin (5-HT) receptor activity and inhibition of the serotonin transporter. METHOD: Adults aged 18-75 years with MDD (DSM-IV-TR) and Montgomery-Asberg Depression Rating Scale (MADRS) total score ≥ 26 were randomized (1:1:1) to receive vortioxetine 10 mg or 15 mg or placebo once daily, with the primary efficacy end point being change from baseline at week 8 in MADRS analyzed by mixed model for repeated measures...
May 2015: Journal of Clinical Psychiatry
https://www.readbyqxmd.com/read/26035185/a-randomized-double-blind-placebo-controlled-study-of-the-efficacy-and-safety-of-vortioxetine-10-mg-and-20-mg-in-adults-with-major-depressive-disorder
#16
RANDOMIZED CONTROLLED TRIAL
Paula L Jacobsen, Atul R Mahableshwarkar, Michael Serenko, Serena Chan, Madhukar H Trivedi
CONTEXT: Vortioxetine (Lu AA21004) is an antidepressant with a mechanism of action thought to be related to a combination of 2 pharmacologic actions: direct modulation of several receptors and inhibition of the serotonin transporter. OBJECTIVE: To evaluate the efficacy of vortioxetine 10 and 20 mg once daily in outpatients with major depressive disorder. DESIGN, SETTING, AND PARTICIPANTS: This 8-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study was conducted from July 2010 to January 2012 among adults with a primary diagnosis of recurrent major depressive disorder (DSM-IV-TR)...
May 2015: Journal of Clinical Psychiatry
https://www.readbyqxmd.com/read/26020712/safety-and-tolerability-of-vortioxetine-15-and-20%C3%A2-mg-in-patients-with-major-depressive-disorder-results-of-an-open-label-flexible-dose-52-week-extension-study
#17
RANDOMIZED CONTROLLED TRIAL
Paula L Jacobsen, Linda Harper, Lambros Chrones, Serena Chan, Atul R Mahableshwarkar
Vortioxetine is approved for the treatment of adults with major depressive disorder. This open-label extension (OLE) study evaluated the safety and tolerability of vortioxetine in the long-term treatment of major depressive disorder patients, as well as evaluated its effectiveness using measures of depression, anxiety, and overall functioning. This was a 52-week, flexible-dose, OLE study in patients who completed one of three randomized, double-blind, placebo-controlled, 8-week vortioxetine trials. All patients were switched to 10 mg/day vortioxetine for week 1, then adjusted between 15 and 20 mg for the remainder of the study, but not downtitrated below 15 mg...
September 2015: International Clinical Psychopharmacology
https://www.readbyqxmd.com/read/25907797/vortioxetine-a-multimodal-antidepressant-or-another-selective-serotonin-reuptake-inhibitor
#18
REVIEW
Nicholas A Keks, Judy Hope, Christine Culhane
OBJECTIVE: The treatment of depressive disorders remains unsatisfactory for many patients with regard to efficacy and tolerability. Vortioxetine has been registered by regulatory authorities for the treatment of major depressive disorder. This paper aims to provide clinicians with a brief overview of vortioxetine and its place in treatment. CONCLUSIONS: Vortioxetine is a serotonin reuptake inhibitor with additional serotonergic receptor effects of uncertain significance; hence, its classification as 'multimodal'...
June 2015: Australasian Psychiatry: Bulletin of Royal Australian and New Zealand College of Psychiatrists
https://www.readbyqxmd.com/read/25893002/depression-and-cerebrovascular-disease-could-vortioxetine-represent-a-valid-treatment-option
#19
Mauro Giovanni Carta, Andrea Norcini Pala, Gabriele Finco, Mario Musu, Maria Francesca Moro
Depression and cerebrovascular atherosclerosis often occur in comorbidity showing neuropsychological impairment and poor response to antidepressant treatment. Objective is to evaluate if new antidepressant vortioxetine may be a potential treatment option. Mechanism of Action : Vortioxetine has 5-HT3, 5-HT7 and 5-HT1D antagonists, 5-HT1B partial agonist and a 5-HT1A agonist and serotonin transporter inhibitor property. Efficacy and safety in Major Depressive Disorders and in cognitive impairment : The majority of trials (one of them in older people) showed efficacy for vortioxetine against placebo and no differences against other active treatments...
2015: Clinical Practice and Epidemiology in Mental Health: CP & EMH
https://www.readbyqxmd.com/read/25874839/the-safety-and-efficacy-of-vortioxetine-for-acute-treatment-of-major-depressive-disorder-a-systematic-review-and-meta-analysis
#20
REVIEW
Amanda S Meeker, Megan C Herink, Dean G Haxby, Daniel M Hartung
BACKGROUND: Vortioxetine is the first mixed serotonin agonist and antagonist antidepressant approved in the US. We sought to evaluate all published and unpublished data available to determine the efficacy and harms of vortioxetine in adults with major depressive disorder. METHODS: We used a predefined search strategy of MEDLINE, the Cochrane Central Register of Controlled Trials, ClinicalTrials.gov, and Drugs@FDA to identify studies evaluating vortioxetine in the acute treatment of major depressive disorder...
March 1, 2015: Systematic Reviews
keyword
keyword
170193
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"